Organizations, academicians and individuals continue to press companies to share their intellectual property for use in the battle against COVID-19. The call has gained traction, as drug and vaccine makers form collaborations and share their libraries of compounds. But a bigger issue may arise in assuring that products are widely available once they are approved.
Most recently, an international coalition of scientists and lawyers asked patent holders to commit to making their intellectual property available...
